ea0049gp241 | Thyroid Cancer & Thyroid Case Reports | ECE2017
Peiro I
, Martin L San
, Simo-Servat A
, Otero J
, Ruffinelli JC
, Nadal E
, Iglesias P
, Diez JJ
, Villabona C
Introduction: Nivolumab is an antibody that binds to and blocks the activation of programmed-death-receptor 1(PD-1), promoting the activation of T-cells against tumor cells. Thyroid dysfunction (TD) is one of the most common immuno-related adverse events, with incidence up to 10% in patients treated with PD-1/PD-L1 blockade.Objective: To report our experience of Nivolumab-TD in patients with advanced cancer.Methods: All patients di...